You are here

Award Data

For best search results, use the search terms first and then apply the filters
Reset

The Award database is continually updated throughout the year. As a result, data for FY24 is not expected to be complete until March, 2025.

Download all SBIR.gov award data either with award abstracts (290MB) or without award abstracts (65MB). A data dictionary and additional information is located on the Data Resource Page. Files are refreshed monthly.

The SBIR.gov award data files now contain the required fields to calculate award timeliness for individual awards or for an agency or branch. Additional information on calculating award timeliness is available on the Data Resource Page.

Displaying 202301 - 202310 of 207699 results
  1. Exploiting porcine cytomegalovirus stealth mechanisms

    SBC: Xenocept, Inc.            Topic: N/A

    DESCRIPTION (provided by applicant): Pig-to-human xenotransplantation may alleviate the critical shortage of organs available for transplantation. However, hyperacute rejection (HAR), acute vascular rejection (AVR), and cell-mediated rejection pose significant immunological hurdles to making xenotransplantation a clinical reality. Now that pigs lacking a functional alpha-1,3-galactosyltransferase ...

    SBIR Phase I 2005 Department of Health and Human ServicesNational Institutes of Health
  2. Spectroscopic identification /removal of PMMA from bone

    SBC: Remspec Corp            Topic: N/A

    DESCRIPTION (provided by applicant): The objective is to develop a fiber optic-based, real-time, in-situ method for distinguishing bone from polymethyl methacrylate (PMMA) cement during replacement hip arthroplasty surgery. The proposed method is based on near-infrared (NIR) spectroscopy, which has been shown to be a viable method for distinguishing bone and PMMA in the laboratory. The program is ...

    SBIR Phase I 2005 Department of Health and Human ServicesNational Institutes of Health
  3. Muscle-directed gene therapy for Crigler-Najjar Syndrome

    SBC: MIRUS BIO CORPORATION            Topic: N/A

    DESCRIPTION (provided by applicant): Our goal is the development of a clinically applicable, non-viral, muscle-directed gene therapy for Crigler- Najjar Syndrome Type I (CN-I). Due to mutations in the bilirubin UDP-glucuronosyltransferase (UGT1A1) gene, CN-I patients cannot excrete bilirubin. The resulting hyperbilirubinemia causes toxic brain damage. Treatment modalities are aimed at decreasing s ...

    SBIR Phase I 2005 Department of Health and Human ServicesNational Institutes of Health
  4. Internet Savvy Caregiver: Dementia Training and Planner

    SBC: HEALTHCARE INTERACTIVE, INC.            Topic: N/A

    DESCRIPTION (provided by applicant): The overall goal of the Internet-Based Savvy Caregiver (IBSC) program is to develop and bring to market an Internet-based psycho-educational program designed to provide persons caring for relatives who have dementing disorders the knowledge, skills, and outlook they need to undertake and succeed in the caregiving role they have assumed. The IBSC program is comp ...

    SBIR Phase I 2005 Department of Health and Human ServicesNational Institutes of Health
  5. Magnetohydrodynamic-based Laboratories on a Chip

    SBC: VEGRANDIS, LLC            Topic: N/A

    DESCRIPTION (provided by applicant): In this Phase II project, Vegrandis, LLC proposes to develop a magnetohydrodynamic (MHD) microfluidic based "sample-in, answer-out" bioassay chip for diagnosis of ovarian cancer. The proposed bioassay chip will use MHD microfluidics to pump the sample and reagents necessary to perform the assay and will have integrated micro-electrochemical detection of a panel ...

    SBIR Phase II 2005 Department of Health and Human ServicesNational Institutes of Health
  6. Novel Proteins for Treatment of Bowel Diseases

    SBC: PROTEOS, INC.            Topic: N/A

    DESCRIPTION (provided by applicant): The goal of this Phase 1 proposal is to optimize the activity and minimize the size of a protein therapeutic for intestinal bowel diseases (IBD), in order to enable production of the protein in quantities needed for trials in humans. Currently, there is no safe and effective treatment for IBD. Professor Samuel Ho and colleagues at the University of Minnesota ha ...

    SBIR Phase I 2005 Department of Health and Human ServicesNational Institutes of Health
  7. A2a Adenosine Agonists for Diabetic Nephropathy

    SBC: ADENOSINE THERAPEUTICS, LLC            Topic: N/A

    DESCRIPTION (provided by applicant): Diabetic nephropathy (DN) accounts for approximately 40% of the cases of renal failure requiring dialysis or transplantation. Moreover, diabetic nephropathy is associated with markedly higher morbidity and mortality rates. It is important to develop novel interventions to prevent complications of diabetes. Inflammation in the genesis of diabetes, as well as its ...

    SBIR Phase I 2005 Department of Health and Human ServicesNational Institutes of Health
  8. Point Source Ozonation to Minimize Antibiotic Resistance

    SBC: BLUEINGREEN, LLC            Topic: N/A

    DESCRIPTION (provided by applicant): BluelnGreen, LLC proposes to develop an effective, versatile and cost efficient device for the application of ozone micro-bubbles to the effluent of critical point sources of medical wastewater (hospitals, large clinics and pharmaceutical manufacturing plants) to reduce the overall amount of both antibiotic residuals and resistant pathogens that are released t ...

    SBIR Phase I 2005 Department of Health and Human ServicesNational Institutes of Health
  9. Internet-based Fidelity Enhancement of MTFC

    SBC: Tfc Consultants, Inc.            Topic: N/A

    DESCRIPTION (provided by applicant): The fields of mental health, child welfare, and juvenile justice are jointly faced with the challenge of reducing the prevalence of antisocial behavior among adolescents. In the last 20 years, conduct disorders have moved from being considered intractable difficulties to having difficult but available solutions. Empirically-validated interventions are now being ...

    SBIR Phase I 2005 Department of Health and Human ServicesNational Institutes of Health
  10. Improved Protein Mapping for Fragment-Based Drug Design

    SBC: Solmap Pharmaceuticals, Inc.            Topic: N/A

    DESCRIPTION (provided by applicant): Computational solvent mapping methods place molecular probes - small molecules or functional groups - on a protein surface in order to identify the most favorable binding positions. Although X-ray crystallography and NMR show that small organic molecules preferentially cluster in the binding site, current computational methods yield hundreds of energy minima o ...

    SBIR Phase I 2005 Department of Health and Human ServicesNational Institutes of Health
US Flag An Official Website of the United States Government